Drug General Information
Drug ID	D09DJC
Former ID	DNCL002746
Drug Name	IRX4204
Drug Type	Small molecular drug
Indication	Prostate cancer [ICD9: 185; ICD10:C61]		Phase 1	[525182]
Company	Io Therapeutics
Structure		Download 2D MOL 3D MOL
Formula	C24H32O2
PubChem Compound ID	9863341
Target and Pathway
Target(s)	Retinoic acid receptor RXR-gamma	Target Info	Modulator
KEGG Pathway	PPAR signaling pathway
	Thyroid hormone signaling pathway
	Adipocytokine signaling pathway
	Pathways in cancer
	Transcriptional misregulation in cancer
	Thyroid cancer
	Small cell lung cancer
	Non-small cell lung cancer
Pathway Interaction Database	Regulation of Androgen receptor activity
	RXR and RAR heterodimerization with other nuclear receptor
	Retinoic acid receptors-mediated signaling
	a6b1 and a6b4 Integrin signaling
Reactome	Nuclear Receptor transcription pathway
WikiPathways	Vitamin A and Carotenoid Metabolism
	Adipogenesis
	Nuclear Receptors
References
Ref 525182	ClinicalTrials.gov (NCT02438215) Study of IRX4204 for Treatment of Early Parkinson's Disease. U.S. National Institutes of Health.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.